Parameter | Total (n = 76) | ueSRT (n = 20) | eSRT (n = 40) | dSRT (n = 16) | P |
---|---|---|---|---|---|
Age at surgery, years, median (IQR) | 65 (61–69) | 68 (61–72) | 65 (61–69) | 64 (57–67) | 0.0574a |
Initial PSA, ng/mL, median (IQR) | 8.7 (6.4–12.6) | 9.2 (6.9–12.6) | 8.4 (5.9–13.0) | 9.3 (7.2–12.9) | 0.6684a |
Pathological T stage, no. (%): | |||||
T2 | 37 (49) | 9 (45) | 21 (53) | 7 (44) | 0.0834b |
T3a | 35 (46) | 10 (50) | 19 (48) | 6 (38) | |
T3b | 4 (5) | 1 (5) | 0 (0) | 3 (19) | |
Pathological GS, no. (%): | |||||
≤6 | 12 (16) | 3 (15) | 6 (15) | 3 (19) | 0.1533b |
7 | 49 (64) | 16 (80) | 26 (65) | 7 (44) | |
≥8 | 15 (20) | 1 (5) | 8 (20) | 6 (38) | |
Gleason pattern 5 (including tertiary 5) | 27 (36) | 5 (25) | 14 (35) | 8 (50) | 0.2959b |
Extraprostatic extension, no. (%) | 37 (49) | 10 (50) | 18 (45) | 9 (56) | 0.7416b |
Lymphovascular invasion, no. (%) | 21 (28) | 3 (15) | 10 (25) | 8 (50) | 0.0568b |
Positive surgical margin, no. (%) | 57 (75) | 17 (85) | 28 (70) | 12 (75) | 0.4493b |
Seminal vesicle invasion, no. (%) | 4 (5) | 1 (5) | 0 (0) | 3 (19) | 0.0178*b |
Perineural invasion, no. (%) | 58 (76) | 17 (85) | 28 (70) | 13 (81) | 0.3805b |
SRT technique, no. (%): | |||||
3DCRT | 61 (80) | 19 (95) | 27 (68) | 15 (94) | 0.0130*b |
IMRT | 15 (20) | 1 (5) | 13 (33) | 1 (6) | |
Total dose, no. (%): | |||||
60–65 Gy | 10 (13) | 3 (15) | 5 (13) | 2 (13) | 0.9646b |
66 Gy | 60 (79) | 16 (80) | 31 (78) | 13 (81) | |
70 Gy | 6 (8) | 1 (5) | 4 (10) | 1 (6) | |
Concomitant ADT, no. (%) | 12 (16) | 5 (25) | 2 (5) | 5 (31) | 0.0218*b |
PSA doubling time, months, median (IQR) | 8.4 (4.6–20.1) | –† | 12.7 (6.2–25.1) | 5.9 (3.5–14.3) | – |
Median follow-up, months (IQR) | 70 (48–95) | 74 (57–99) | 73 (43–83) | 58 (41–99) | 0.5386a |